Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist
Contact+90 (538) 677 60 18

FDA Approved the Rapid Coronavirus (SARS-CoV-2) Test

FDA Approved the Rapid Coronavirus (SARS-CoV-2) Test
In this article

The US Food and Drug Administration (FDA) approved the Xpert® Xpress SARS-ÇoV-2 rapid molecular diagnostic test for use in detecting the novel coronavirus. The test was designed to run on the device system called "23.000 Cepheid Xpert", which operates in many parts of the world. With this system, a sputum sample can be tested for the virus in 45 minutes. One of the most important needs in the fight against the SARS-CoV-2 outbreak is for systems that can provide a rapid diagnosis. The Xpert*Xpress system offers fully automated, very rapid diagnosis. Sample preparation takes less than 1 minute.

How Does the Xpert- Xpress SARS COV 2 Test Work?

In this system, genomic sequences specific to SARS-CoV-2 are detected using polymerase chain reaction (PCR); this is therefore a rapid PCR test. In other words, this diagnostic system is based on a rapid, easy-to-use nucleic acid amplification test.

The Xpert system first separates the virus from the samples provided. It then isolates the virus's genomic material using sonication sound waves. Finally, it rapidly amplifies this genomic material using polymerase chain reaction. This process identifies the regions of the virus that are most clinically relevant. The test can provide results in as little as 45 minutes. Doctors can perform this test even in their own offices. It is important to emphasize that the FDA has granted this test emergency use authorization. It was announced that marketing would begin the following week. This system had previously been used successfully in the diagnosis of tuberculosis and HIV.

Sources

1. Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic
fda.gov - 21 March 2020.

2. Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test.
cepheid.mediaroom.com
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

FDA Approved the Rapid Coronavirus (SARS-CoV-2) Test

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy